OP0164 SAFETY AND EFFICACY OF UPADACITINIB FOR PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: AN INTERIM ANALYSIS OF AN OPEN-LABEL, PHASE 1 TRIAL

医学 内科学 青少年类风湿关节炎 痹症科 关节炎 中期分析 类风湿性关节炎 不利影响 临床终点 临床试验
作者
Hermine I. Brunner,Gerd Horneff,Ivan Foeldvari,Jordi Antón,M. E. Mohamed,Yingzhi Qian,Kristina Unnebrink,Siguo Hao,Heidi S. Camp,N. Khan,A. Shmagel
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:: 108.2-109 被引量:2
标识
DOI:10.1136/annrheumdis-2023-eular.3987
摘要

Background

Novel treatment options are needed for pediatric patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). Upadacitinib (UPA) is an oral, selective Janus kinase (JAK) inhibitor with a positive benefit-risk profile in adult patients with moderate-to-severe active rheumatoid arthritis.[1,2]

Objectives

To evaluate the safety and efficacy of UPA in pediatric patients with pcJIA.

Methods

This open-label, 3-part, phase 1 trial (NCT03725007) enrolled pediatric patients aged 2 to < 18 years with pcJIA and ≥ 5 active joints at 31 sites across North America, Europe, and Asia. UPA was dosed as a twice-daily oral solution or once-daily tablet based on body weight. Part 1 evaluated multiple ascending doses of UPA for 7 days. Parts 2 and 3 evaluated long-term safety and efficacy of UPA for up to 156 weeks. This interim analysis (cutoff date of 22 September 2022) evaluated all available safety data in parts 1, 2, and 3; efficacy was evaluated in parts 1 and 2 through week 12. Efficacy endpoints included the JIA American College of Rheumatology (JIA ACR) 30, 50, and 70 response; the Childhood Health Assessment Questionnaire (C-HAQ); and the 27-point Juvenile Arthritis Disease Activity Score based on C-reactive Protein (JADAS-27 [CRP]).

Results

A total of 57 pediatric patients (78.9% female) with mean (SD) age of 9.5 (4.4) years and mean (SD) weight of 38.1 (20.4) kg received UPA; of these, 51 patients were treated in parts 1 and 2. In part 1, 8 (15.7%) of 51 patients reported adverse events (AEs) through 7 days; no patients reported serious AEs or AEs leading to treatment discontinuation. At a mean (median) duration of exposure of 514.9 (412.0) days, 52 (91.2%) of 57 patients reported AEs that were predominately mild to moderate in severity (Table 1). The most common treatment-emergent AEs were COVID-19 infection (n = 23/57, 40.4%), upper respiratory tract infection (n = 23/57, 40.4%), nasopharyngitis (n = 13/57, 22.8%), gastroenteritis (n = 10/57, 17.5%), pyrexia (n = 10/57, 17.5%), abdominal pain (n = 9/57, 15.8%), and nausea (n = 8/57, 14.0%). The most common AEs of special interest included elevated creatine phosphokinase levels (n = 6/57, 10.5%), hepatic disorder (n = 3/57, 5.3%), and neutropenia (n = 2/57, 3.5%); all were nonserious events. Six (31.6%) of 19 patients in the group aged 12 to <18 years reported serious AEs and 2 (10.5%) reported AEs leading to treatment discontinuation. A high proportion of patients across all age groups achieved JIA ACR30, 50, and 70 response at week 12 (Figure 1). Improvement from baseline to week 12 in C-HAQ and JADAS-27 [CRP] scores was observed across all age groups.

Conclusion

In pediatric patients with pcJIA, UPA was well tolerated and associated with improvements in disease activity and physical function at week 12.

References

[1] Burmester GR, et al. Lancet. 2018;391:2503-12. [2] Smolen JS, et al. Lancet. 2019;393:2303-11.

Acknowledgements

AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approving the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. All authors agreed to submit this abstract to the EULAR 2023 Congress. Medical writing support was provided by Michael Dyle, PhD, of JB Ashtin, and funded by AbbVie.

Disclosure of Interests

Hermine Brunner Speakers bureau: GlaxoSmithKline, Novartis, and Pfizer, Consultant of: AbbVie, Astra Zeneca-Medimmune, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cerocor, Eli Lilly, EMD Serono, Idorsia, Janssen, GlaxoSmithKline, F Hoffmann-La Roche, Merck, Novartis, R-Pharm, and Sanofi, Gerd Horneff Grant/research support from: AbbVie, Bayer, Chugai, GlaxoSmithKline, MSD, Novartis, Pfizer, Roche, Sanofi, and Sobi, Ivan Foeldvari Consultant of: Eli Lilly, Hexal, Medac, Novartis, and Pfizer, Jordi Anton Consultant of: AbbVie, Alexion, Amgen, Gebro, GSK Lilly, Novartis, Novimmune, Pfizer, Roche, Sanofi, Sobi, and Lilly, Grant/research support from: AbbVie, Alexion, Amgen, Gebro, GSK Lilly, Novartis, Novimmune, Pfizer, Roche, Sanofi, Sobi, and Lilly, Mohamed-Eslam Mohamed Shareholder of: May hold AbbVie stock or stock options, Employee of: AbbVie, Yuli Qian Shareholder of: May hold AbbVie stock or stock options, Employee of: AbbVie, Kristina Unnebrink Shareholder of: May hold AbbVie stock or stock options, Employee of: AbbVie, Shuai Hao Shareholder of: May hold AbbVie stock or stock options, Employee of: AbbVie, Heidi Camp Shareholder of: May hold AbbVie stock or stock options, Employee of: AbbVie, Nasser Khan Shareholder of: May hold AbbVie stock or stock options, Employee of: AbbVie, Anna Shmagel Shareholder of: May hold AbbVie stock or stock options, Employee of: AbbVie.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星星发布了新的文献求助10
刚刚
万能图书馆应助wusuowei采纳,获得10
1秒前
斯文败类应助xcc采纳,获得10
2秒前
kingtongx应助Lu采纳,获得10
2秒前
Jattck发布了新的文献求助30
3秒前
上官若男应助huayi采纳,获得10
4秒前
lalala发布了新的文献求助10
4秒前
Malmever发布了新的文献求助30
5秒前
ottsannn完成签到,获得积分10
5秒前
大个应助蓦然回首采纳,获得10
5秒前
Dou_Xiaowen发布了新的文献求助10
6秒前
6秒前
baobaobaozi完成签到,获得积分20
6秒前
jyy应助包子采纳,获得10
7秒前
CodeCraft应助Cc采纳,获得10
8秒前
8秒前
9秒前
11秒前
黑风小妖完成签到,获得积分10
11秒前
12秒前
12秒前
hi应助爱偷懒的猪采纳,获得10
14秒前
星星完成签到,获得积分20
15秒前
大模型应助无情白羊采纳,获得10
15秒前
快乐滑板发布了新的文献求助10
15秒前
15秒前
永毅完成签到 ,获得积分10
15秒前
言亦云应助顺利的雁采纳,获得30
16秒前
豆花发布了新的文献求助50
16秒前
16秒前
hhhhhhhhh完成签到,获得积分10
17秒前
guoguo发布了新的文献求助10
17秒前
17秒前
隐形曼青应助杨乙友采纳,获得10
18秒前
18秒前
19秒前
20秒前
雨齐完成签到,获得积分10
21秒前
23秒前
23秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969557
求助须知:如何正确求助?哪些是违规求助? 3514377
关于积分的说明 11173836
捐赠科研通 3249692
什么是DOI,文献DOI怎么找? 1794979
邀请新用户注册赠送积分活动 875537
科研通“疑难数据库(出版商)”最低求助积分说明 804836